Search Results - "Pignochino, Y."

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study by Grignani, G., Palmerini, E., Dileo, P., Asaftei, S.D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P.G., Ferrari, S., Aglietta, M.

“…After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades. Recently,…”
Get full text

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment by Fioramonti, M., Fausti, V., Pantano, F., Iuliani, M., Ribelli, G., Lotti, F., Pignochino, Y., Grignani, G., Santini, D., Tonini, G., Vincenzi, B.

“…Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Due to its high heterogeneity and to survival signals from bone microenvironment, OS…”
Get full text

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells by Leuci, V., Casucci, M., Grignani, G., Rotolo, R., Rossotti, U., Vigna, E., Gammaitoni, L., Mesiano, G., Fiorino, E., Donini, C., Pisacane, A., ambrosio, L. D., Pignochino, Y., Aglietta, M., Bondanza, A., Sangiolo, D.

“…Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based on cytokine-induced killer cells (CIK) redirected with…”
Get full text

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma by Peraldo-Neia, C, Ostano, P, Cavalloni, G, Pignochino, Y, Sangiolo, D, De Cecco, L, Marchesi, E, Ribero, D, Scarpa, A, De Rose, A M, Giuliani, A, Calise, F, Raggi, C, Invernizzi, P, Aglietta, M, Chiorino, G, Leone, F

“…Effective target therapies for intrahepatic cholangiocarcinoma (ICC) have not been identified so far. One of the reasons may be the genetic evolution from…”
Get full text

350 Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitors Potentiate Trabectedin Activity in Preclinical Models of Bone and Soft Tissue Sarcomas by Pignochino, Y, Capozzi, F, Dell'Aglio, C, Basiricò, M, D'ambrosio, L, Galizia, D, Palesandro, E, Benassi, M.S, Aglietta, M, Grignani, G

Get full text

133 mTOR is a druggable molecule in Malignant Pleural Mesothelioma targeted therapy: antiproliferative effect of sorafenib and everolimus in preclinical models by Pignochino, Y, Inghilleri, S, Zorzetto, M, Luisetti, M, Morbini, P, Aglietta, M, Pozzi, E, Stella, G

Get full text

134 Dissecting the mTOR pathway in osteosarcoma by Pignochino, Y, Grignani, G, Basiricò, M, Motta, M, Bruno, S, Cavalloni, G, Aliberti, S, Picci, P, Alberghini, M, Aglietta, M

Get full text

LBA91 TOMAS2: A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard treatments by D'Ambrosio, L., Merlini, A., Brunello, A., Ferraresi, V., Paioli, A., Vincenzi, B., Pantaleo, M.A., De Pas, T.M., Gurrieri, L., Sanfilippo, R., Buonadonna, A., Baldi, G.G., Badalamenti, G., Marchiò, C., Pignochino, Y., Manessi, G., Aliberti, S., Dei Tos, A.P., Stacchiotti, S., Grignani, G.

Get full text

1633P Explorative model of imatinib resistant wild type GIST and potential immunotherapy strategies by Fiorino, E., Mesiano, G., Cerviere, I., Berrino, E., D’Ambrosio, L., Merlini, A., Venesio, T., Pignochino, Y., Pisacane, A., Gammaitoni, L., Grignani, G., Aglietta, M., Sangiolo, D.

Get full text

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study by Cova, Emanuela, Pandolfi, Laura, Colombo, Miriam, Frangipane, Vanessa, Inghilleri, Simona, Morosini, Monica, Mrakic-Sposta, Simona, Moretti, Sarah, Monti, Manuela, Pignochino, Ymera, Benvenuti, Silvia, Prosperi, Davide, Stella, Giulia, Morbini, Patrizia, Meloni, Federica

“…Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos…”
Get full text

Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma by LEONE, Francesco, CAVALLONI, Giuliana, PIGNOCHINO, Ymera, SAROTTO, Ivana, FERRARIS, Renato, PIACIBELLO, Wanda, VENESIO, Tiziana, CAPUSSOTTI, Lorenzo, RISIO, Mauro, AGLIETTA, Massimo

“…Objective: Conventional therapies are still unsuccessful in patients with carcinoma arising from the biliary tract. Somatic mutations of the epidermal growth…”
Get full text

Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers by TODOROVIC, Maja, MESIANO, Giulia, PIACIBELLO, Wanda, ELIA, Angela Rita, PIGNOCHINO, Ymera, DELL'AGLIO, Carmine, GRIGNANI, Giovanni, CIGNETTI, Alessandro, AGLIETTA, Massimo, SANGIOLO, Dario, GAMMAITONI, Loretta, LEUCI, Valeria, GIRAUDO DIEGO, Lidia, CAMMARATA, Cristina, JORDANEY, Noela, CARNEVALE-SCHIANCA, Fabrizio, GALLO, Susanna, FAGIOLI, Franca

“…Cytokine-induced killer cells (CIKs) are ex vivo expanded T-NK lymphocytes capable of HLA-unrestricted antitumor activity. CIKs are promising candidates for…”
Get full text

Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of osteosarcoma (OS) by Pignochino, Y., Grignani, G., Basiricò, M., Cavalloni, G., Motta, M., Bruno, S., Aliberti, S., Alberghini, M., Picci, P., Aglietta, M.

“…Abstract only…”
Get full text

Antitumor activity of sorafenib in osteosarcoma (OS) preclinical models by Pignochino, Y., Grignani, G., Cavalloni, G., Motta, M., Bruno, S., Camussi, G., Ferrari, S., Picci, P., Berger, M., Aglietta, M.

“…Abstract only…”
Get full text

Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma by Aglietta, M., Pignochino, Y., Cavalloni, G., Sarotto, I., Penachioni, J., Zanon, C., Migliardi, G., Piacibello, W., Risio, M., Bardelli, A., Leone, F.

“…Abstract only 4582 Background: Biliary tract carcinomas express EGFR and are potential candidates to EGFR target therapies. We recently described somatic…”
Get full text

Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab by Cavalloni, Giuliana, Sarotto, Ivana, Pignochino, Ymera, Gammaitoni, Loretta, Migliardi, Giorgia, Sgro, Luca, Piacibello, Wanda, Risio, Mauro, Aglietta, Massimo, Leone, Francesco

“…The recombinant monoclonal antibody trastuzumab has antiproliferative effect on breast cancer (BC) cells with ErbB2 overexpression. We postulated that a…”
Get full text

Proliferative senescence in hematopoietic stem cells during ex-vivo expansion by Piacibello, Wanda, Gammaitoni, Loretta, Pignochino, Ymera

“…The good outcome of hematopoietic stem cell (HSC) transplantation is hampered by low doses of CD34+ cell infusion. Transplanted HSCs undergo a replicative…”
Get full text

Feasibility of cord blood stem cell manipulation with high-energy shock waves: An in vitro and in vivo study by Berger, Massimo, Frairia, Roberto, Piacibello, Wanda, Sanavio, Fiorella, Palmero, Alessandra, Venturi, Claudio, Pignochino, Ymera, Berta, Laura, Madon, Enrico, Aglietta, Massimo, Fagioli, Franca

“…Cord blood CD34 + cells are more uncommitted than their adult counterparts as they can be more easily maintained and expanded in vitro and transduced with…”
Get full text

Stem cells: overview by Piacibello, W, Pignochino, Y

Get more information

Tumor Cell Purging by Ex Vivo Expansion of Hemopoietic Stem Cells from Breast Cancer Patients Combined with Targeting ErbB Receptors by Leone, Francesco, Cavalloni, Giuliana, Gunetti, Monica, Pignochino, Ymera, Piacibello, Wanda, Aglietta, Massimo

“…Tumor cell contamination might induce relapse after autologous transplantation in breast cancer patients. We used an ex vivo purging strategy to decrease the…”
Get full text